Quick Answer: What Happens to Fat Mass and Lean Mass During Tirzepatide-Associated Weight Loss?
Tirzepatide-associated weight reduction involves both fat-mass loss and lean-mass loss — but the majority of the weight lost in the SURMOUNT-1 DXA substudy came from fat mass.
In the 2025 SURMOUNT-1 body-composition substudy, 160 participants underwent whole-body dual-energy X-ray absorptiometry (DXA) at baseline and Week 72. Among participants receiving pooled tirzepatide doses, body weight decreased by 21.3%, fat mass by 33.9%, and lean mass by 10.9%.
When the components of weight reduction were expressed as proportions of total weight lost, approximately 74% came from fat mass and 26% from lean mass in the tirzepatide group. This is commonly summarized as approximately 75% fat mass and 25% lean mass.
That finding is important for active people because the scale alone cannot tell you what tissue has changed.
However, another distinction is equally important:
DXA-derived lean mass includes lean soft tissue and should not automatically be interpreted as pure skeletal muscle. Current reviews emphasize that preserving the quantity, quality and function of skeletal muscle is a more meaningful goal than simply maximizing the number on a scale.
Therefore, the scientifically useful question is not simply “How much weight can tirzepatide remove?”
It is:
“What is the composition of that weight loss, and what happens to muscle quantity, muscle quality and physical function?”
Key Takeaways
- The SURMOUNT-1 DXA substudy found substantial reductions in both fat mass and lean mass with tirzepatide.
- At Week 72, body weight decreased by 21.3%, fat mass by 33.9%, and lean mass by 10.9% in the pooled tirzepatide group.
- Approximately 74% of weight lost was fat mass and 26% was lean mass in the tirzepatide substudy.
- The commonly used shorthand is approximately 75% fat mass and 25% lean mass.
- Approximately 75/25 does not mean that 25% of muscle tissue was lost.
- DXA lean mass includes lean soft tissue and is not equivalent to direct measurement of skeletal muscle alone.
- Tirzepatide produced a substantially greater absolute reduction in fat mass than lean mass.
- Visceral fat mass decreased by approximately 40.1% in the tirzepatide DXA substudy.
- Body-composition outcomes remained broadly similar across the study’s evaluated age and sex subgroups.
- Active people should therefore evaluate weight loss through more than body weight: muscle quantity, strength, physical function, training capacity and nutritional adequacy are also relevant.
- Current research increasingly focuses on “quality of weight loss” rather than weight reduction alone.
- Resistance exercise and adequate nutritional intake are major research and clinical considerations for preserving lean tissue during weight reduction.
Introduction: A Lower Number on the Scale Is Not a Body-Composition Report
When people discuss weight loss, the most common metric is body weight.
It is easy to understand why.
The scale gives one number, and the number changes over time.
But body weight is a composite measurement.
A person can lose:
- fat mass;
- lean soft tissue;
- body water;
- glycogen-associated water;
- and other components of total body mass.
For someone who is sedentary, this distinction already matters.
For an active person who runs, cycles, swims, lifts weights, practices martial arts or spends weekends hiking around Da Nang, it matters even more.
The question is no longer simply:
“How much weight did I lose?”
It becomes:
“What did I lose?”
That is the central question of body-composition research around tirzepatide.
What the SURMOUNT-1 DXA Substudy Actually Measured
The most directly relevant evidence comes from a body-composition substudy of SURMOUNT-1.
Of the 2,539 participants in the parent SURMOUNT-1 trial, 255 entered the DXA substudy and 160 had baseline and Week 72 or early-discontinuation DXA data available for the efficacy analysis.
The participants had a mean baseline body weight of approximately 102.5 kg and mean BMI of approximately 38.0 kg/m².
Whole-body DXA was used to evaluate:
- fat mass;
- lean mass;
- visceral fat mass;
- body weight;
- and waist circumference.
The important methodological point is that this was not simply a scale-weight analysis.
Researchers were trying to determine which body compartments changed.
The Core Result: 74% Fat Mass, 26% Lean Mass
The headline body-composition result is straightforward.
| Measure at Week 72 | Tirzepatide | Placebo |
|---|---|---|
| Body weight | -21.3% | -5.3% |
| Fat mass | -33.9% | -8.2% |
| Lean mass | -10.9% | -2.6% |
| Visceral fat mass | -40.1% | -7.3% |
| Waist circumference | -18.1 cm | -3.4 cm |
In absolute terms, the tirzepatide group lost approximately 15.9 kg of fat mass and 5.6 kg of lean mass.
The researchers calculated the composition of the weight reduction as approximately 74% fat mass and 26% lean mass.
That is the evidence behind the frequently quoted “75/25” figure.
What Does “75% Fat, 25% Lean” Actually Mean?
Suppose, purely as an illustration, that someone loses 20 kg of body weight.
A 75/25 composition would correspond approximately to:
- 15 kg from fat mass
- 5 kg from lean mass
It does not mean:
- 15 kg of adipose tissue plus 5 kg of skeletal muscle;
- 25% of the person’s muscles disappeared;
- or that every kilogram of lean-mass reduction represents contractile muscle tissue.
This distinction is essential.
The SURMOUNT-1 investigators explicitly define lean mass as fat-free mass minus total bone mineral content, also described as lean soft tissue mass.
That compartment includes tissues other than skeletal muscle.
Therefore, “lean mass loss” should not automatically be translated into “muscle loss.”
Lean Mass Is Not the Same Thing as Muscle
Body-composition terminology can become confusing because different measurement techniques use different definitions.
| Term | What It Means | Why It Matters |
|---|---|---|
| Fat mass | Estimated mass of body fat molecules | Useful indicator of adiposity |
| Lean mass | Lean soft tissue excluding bone mineral content | Broader than skeletal muscle |
| Fat-free mass | All non-fat components, including muscle, organs, bone, water and connective tissues | Not interchangeable with muscle mass |
| Skeletal muscle mass | Contractile skeletal muscle tissue | More directly relevant to strength and physical function |
| Muscle function | Strength, power, endurance and performance | Cannot be inferred from body weight alone |
This is why recent reviews increasingly argue that future obesity trials should move beyond total lean mass and measure muscle quantity, muscle quality and physical function together.
Why Fat Mass Loss Was the Dominant Component
The body-composition pattern in the SURMOUNT-1 DXA substudy was not random.
Fat mass fell by approximately one-third relative to baseline, while lean mass declined by approximately one-tenth.
In absolute terms, the difference was even clearer:
Lean mass: approximately −5.6 kg
The resulting pattern was roughly three kilograms of fat-mass reduction for every kilogram of lean-mass reduction.
This is why the study authors described tirzepatide as producing approximately three times as much fat-mass loss as lean-mass loss in the substudy.
However, this should not be interpreted as evidence that tirzepatide selectively eliminates fat while completely protecting muscle.
Lean mass did decrease.
That is the part active individuals should not ignore.
The Important Question for Active People: What Happens to Muscle?
For an active person, the desired outcome is usually not simply a lower body weight.
The desired phenotype may be closer to:
+
Preserved muscle quantity
+
Preserved strength
+
Preserved physical performance
That is a much higher bar than simply losing kilograms.
A runner may care about maintaining leg strength.
A cyclist may care about power output.
A swimmer may care about training volume and recovery capacity.
A recreational lifter may care about maintaining resistance-training performance.
A younger active expatriate may care about maintaining muscle while reducing excess body fat.
These outcomes cannot be inferred from a scale reading.
Does the 25% Lean-Mass Figure Mean Tirzepatide Causes Major Muscle Loss?
The answer requires nuance.
It demonstrates that lean mass declined during substantial weight reduction.
It does not demonstrate that 25% of the weight lost was skeletal muscle.
It also does not establish that the reduction in lean mass caused clinically meaningful reductions in strength or physical function.
The SURMOUNT-1 DXA substudy did not directly establish a complete muscle-strength or performance phenotype from its DXA measurements.
This is why newer systematic reviews emphasize the difference between lean-mass measurements and direct measures of skeletal muscle quantity or function.
What About Muscle Quality?
Muscle quantity is only one dimension of muscle health.
Researchers are increasingly interested in:
- muscle volume;
- muscle composition;
- intramuscular fat;
- muscle strength;
- physical performance;
- and metabolic function.
This distinction becomes particularly important in obesity.
A person can have a relatively large amount of lean tissue while also having poor muscle quality.
Reducing excess adiposity may improve physical function even when some lean tissue is lost.
Therefore, “lean mass decreased” should not automatically be translated into “health worsened.”
The biological outcome depends on what tissue was lost, what tissue remained, and what happened to function.
The SURMOUNT-1 Result on Visceral Fat Is Especially Relevant
Body composition is not only about total fat mass.
Where the fat is located matters.
In the DXA substudy, visceral fat mass decreased by approximately 40.1% with tirzepatide versus approximately 7.3% with placebo.
This reduction was larger than the relative reduction in total fat mass.
That is important because visceral adiposity is metabolically distinct from simply carrying more subcutaneous fat.
Therefore, body-composition analysis can reveal changes that the bathroom scale cannot see.
Body composition tells you what changed.
Fat distribution tells you where some of that change occurred.
Body Composition Across Age Groups
The investigators also examined clinically relevant subgroups.
Across the evaluated age groups, tirzepatide was associated with greater reductions in body weight and fat mass compared with placebo.
Lean mass was also reduced in most evaluated subgroups.
Importantly, the proportion of weight reduction represented by fat mass remained broadly around the same range across age categories in the tirzepatide group.
The authors specifically noted that tirzepatide was not associated with proportionally greater lean-tissue loss in older participants.
This does not eliminate the importance of muscle preservation in older adults.
It means the data do not support the simplistic conclusion that larger weight loss automatically translates into a disproportionately larger percentage of lean-tissue loss in older participants within this substudy.
Body Composition Across Sex
The substudy also evaluated female and male participants separately.
No significant difference in treatment effect was found between sexes for fat mass, lean mass, body weight, waist circumference or visceral fat mass in the reported analyses.
The proportion of weight reduction attributable to fat mass was approximately 75% in females and 73% in males receiving tirzepatide.
These findings suggest that the broad body-composition pattern was not restricted to one sex within the studied population.
Does More Weight Loss Mean More Lean Mass Loss?
The relationship is not simply “more weight loss equals a worse percentage of muscle loss.”
In the SURMOUNT-1 DXA substudy, participants were divided into weight-reduction tertiles.
Among tirzepatide-treated participants, the proportion of weight loss represented by fat mass was approximately:
- 70% in the lowest weight-reduction tertile;
- 73% in the middle tertile;
- 76% in the highest tertile.
So the proportion of fat loss remained broadly within the same range even as the absolute amount of weight lost increased.
However, the absolute amount of both fat and lean mass lost increased with greater total weight reduction.
This distinction matters:
Why Resistance Training Matters in the Body-Composition Conversation
Once the objective changes from “lose weight” to “improve body composition,” exercise becomes a different scientific question.
The objective is no longer simply to increase calorie expenditure.
Resistance exercise provides a mechanical stimulus to skeletal muscle during an energy-restricted state.
Evidence from broader weight-loss research indicates that resistance exercise can attenuate the loss of fat-free mass and improve strength while weight is being reduced. A 2025 systematic review and meta-analysis found that adding resistance exercise to dietary weight loss protected fat-free mass and increased fat-mass loss compared with dietary restriction alone.
This is one reason modern discussions of incretin-based weight reduction increasingly emphasize muscle preservation rather than simply calorie expenditure.
Protein Is Part of the Body-Composition Equation
Protein availability is another factor relevant to lean tissue during energy restriction.
When energy intake falls substantially, the body must balance reduced energy availability against the ongoing need to maintain tissue.
Adequate dietary protein can support maintenance of lean tissue during weight loss, although protein alone is not a substitute for mechanical loading.
Recent reviews of GLP-1-based obesity pharmacotherapy increasingly propose an integrated framework involving nutritional adequacy, sufficient protein intake and structured resistance exercise rather than relying on a single intervention.
This is especially relevant when appetite is substantially reduced because eating less can unintentionally mean consuming less protein and fewer micronutrients as well.
Why “Just Eat More Protein” Is Also Too Simple
There is a temptation to respond to lean-mass concerns with a single recommendation:
“Just increase protein.”
That is incomplete.
Muscle is a functional tissue.
Its maintenance depends on more than amino-acid availability.
Mechanical loading, energy availability, hormonal environment, recovery, age, baseline muscle mass and overall nutritional adequacy all matter.
Protein can provide building material.
Resistance exercise provides an important anabolic stimulus.
Neither should be treated as a magic shield against all lean-tissue loss.
The Emerging “Quality of Weight Loss” Concept
Modern obesity research is increasingly moving away from the idea that the best treatment is simply the one that produces the largest number on the scale.
A more sophisticated endpoint is quality of weight loss.
This concept asks whether weight reduction preferentially decreases excess adiposity while maintaining:
- skeletal muscle;
- physical strength;
- functional capacity;
- nutritional adequacy;
- bone health;
- and long-term metabolic resilience.
A 2026 review specifically argued that body weight is a tissue-nonspecific endpoint and that future obesity treatment should evaluate muscle quantity, muscle quality, function, nutrition and bone alongside adiposity.
Tirzepatide and the “Metabolic Engine” Concept
Skeletal muscle is not merely a cosmetic tissue.
It is one of the body’s major sites for glucose disposal and an important contributor to whole-body metabolic health.
For active people, skeletal muscle also represents a functional reserve.
That makes the preservation question more important than simply asking whether a person can reach a lower body weight.
A recent cardiovascular-focused review described muscle preservation during incretin-based pharmacotherapy as an important component of maintaining metabolic and cardiovascular resilience.
This does not mean that all lean-mass reduction is pathological.
It means that the quality of the remaining lean tissue matters.
What the SURMOUNT-1 DXA Study Does Not Tell Us
Good scientific interpretation includes understanding the limitations of the measurement.
The substudy provides valuable DXA evidence, but it does not answer every muscle-related question.
It does not establish:
- exactly how much of the lean-mass reduction came from skeletal muscle;
- whether all participants experienced clinically meaningful reductions in muscle strength;
- whether endurance or athletic performance changed;
- whether muscle quality improved, worsened or remained stable in every participant;
- or whether the body-composition pattern remains identical after longer-term treatment.
These limitations are important because the phrase “lean mass” can easily be overinterpreted.
The current evidence therefore supports a more careful statement:
That is what the study directly demonstrates.
What Later Research Is Asking
As incretin-based pharmacotherapy becomes more widely used, researchers are moving toward a more detailed set of questions.
- Can resistance exercise reduce lean-mass loss during tirzepatide therapy?
- Does preserving lean mass translate into better long-term strength and function?
- Which patients are most vulnerable to clinically important muscle loss?
- How much protein is appropriate for different body-composition phenotypes?
- Does the pattern differ between younger active adults and older adults?
- How does baseline muscle mass influence the response?
- Can future therapies preferentially reduce fat while preserving skeletal muscle?
A 2026 randomized-trial protocol, LEAN-PREP, is specifically designed to investigate whether resistance exercise and/or protein supplementation can preserve muscle mass and physical function during semaglutide or tirzepatide therapy. The existence of the protocol is evidence of an active research question, not evidence that the intervention has already been proven effective in that specific setting.
Da Nang Expat Lens: The Active-Person Problem
Da Nang creates an interesting context for thinking about body composition.
The city attracts people who may be physically active without necessarily identifying as athletes.
That can include:
- runners along the coast;
- cyclists;
- surfers;
- swimmers;
- gym users;
- hikers;
- martial-arts practitioners;
- and people who simply walk extensively as part of daily life.
For these groups, losing body weight is not necessarily the only objective.
A lighter body can be useful for movement.
But losing functional muscle may work against performance.
Therefore, an active-person framework should focus on:
- body-fat reduction;
- lean-tissue preservation;
- strength maintenance;
- training capacity;
- adequate nutritional intake;
- and physical function.
That is a fundamentally different objective from simply chasing the lowest possible scale weight.
What Should an Active Person Monitor?
Body composition should ideally be interpreted alongside functional measures.
| Metric | What It Tells You |
|---|---|
| Body weight | Total mass change |
| Fat mass | Change in adiposity |
| Lean mass | Change in lean soft tissue, not pure muscle |
| Waist circumference | Change in central body size |
| Strength | Functional muscle performance |
| Training performance | Real-world physical capacity |
| Nutritional adequacy | Whether reduced intake is compromising tissue maintenance |
No single metric tells the entire story.
This is precisely why body-composition science is more informative than scale weight alone.
A Practical Scientific Framework: Weight Loss vs Body-Composition Change
| Question | Weight-Loss View | Body-Composition View |
|---|---|---|
| Did weight decrease? | Yes / no | First question, not the final question |
| Where did the weight come from? | Usually ignored | Fat vs lean compartments |
| Was visceral fat reduced? | Not visible on the scale | Important body-composition outcome |
| Was muscle preserved? | Cannot determine | Requires lean-tissue and ideally muscle/function assessment |
| Did strength change? | Not captured | Important functional endpoint |
Expert Insight #1: 25% Lean Mass Does Not Mean 25% Muscle Loss
Expert Insight: The most common misinterpretation of the SURMOUNT-1 DXA study is to convert “26% of weight loss came from lean mass” into “26% of muscle was lost.” Those are not equivalent statements. DXA-derived lean mass represents lean soft tissue and includes components beyond skeletal muscle. The study provides strong evidence of body-composition change, but it does not quantify pure skeletal-muscle loss as a percentage of total muscle tissue.
Expert Insight #2: The Goal Is Not Zero Lean-Mass Change at Any Cost
Expert Insight: Some lean-tissue reduction commonly accompanies substantial weight loss. The scientifically meaningful goal is therefore not necessarily “zero lean-mass change,” but favorable body recomposition: substantial reduction in excess adiposity while maintaining as much functional skeletal muscle, strength and physical capacity as reasonably possible. Recent literature increasingly frames this as the quality of weight loss.
Statistics & Evidence Snapshot
| Finding | Tirzepatide Result | Why It Matters |
|---|---|---|
| DXA substudy | n=160 with baseline and follow-up DXA | Direct body-composition evidence |
| Body weight | −21.3% | Substantial total weight reduction |
| Fat mass | −33.9% | Fat mass was the dominant component of weight loss |
| Lean mass | −10.9% | Lean tissue also decreased |
| Absolute fat-mass change | −15.9 kg | Large absolute reduction in adipose mass |
| Absolute lean-mass change | −5.6 kg | Meaningful lean-tissue reduction requiring interpretation |
| Composition of weight lost | ~74% fat / ~26% lean | Basis of the commonly cited 75/25 figure |
| Visceral fat mass | −40.1% | Central adiposity decreased substantially |
Frequently Asked Questions
In the SURMOUNT-1 DXA substudy, tirzepatide reduced body weight, fat mass and lean mass. At Week 72, body weight fell 21.3%, fat mass 33.9%, and lean mass 10.9% in the pooled tirzepatide group.
Approximately. The study calculated 74% of weight reduction as fat mass and 26% as lean mass. The commonly used shorthand is approximately 75/25.
No. DXA-derived lean mass is broader than skeletal muscle. The 25% figure describes the proportion of total weight reduction attributed to lean mass, not the percentage of a person’s muscle tissue that disappeared.
Mean absolute fat-mass reduction was approximately 15.9 kg with pooled tirzepatide doses.
Mean absolute lean-mass reduction was approximately 5.6 kg in the pooled tirzepatide group. This represents DXA-derived lean mass and should not be interpreted as 5.6 kg of pure skeletal muscle loss.
Yes. In the DXA substudy, visceral fat mass decreased by approximately 40.1% with tirzepatide versus 7.3% with placebo.
That conclusion would be too broad. Lean mass decreased, but the measurement does not equal pure skeletal muscle, and the substudy does not by itself establish clinically meaningful impairment of muscle strength or physical performance.
Because body weight is not the same as physical capacity. Maintaining skeletal muscle, strength and function can matter for running, cycling, swimming, resistance training and long-term metabolic health.
Broader weight-loss research supports resistance exercise as a strategy for attenuating fat-free-mass loss and improving strength. Specific evidence during tirzepatide therapy is still developing.
Nutritional adequacy and sufficient protein are increasingly considered important components of lean-mass preservation during incretin-based weight reduction. Exact requirements should be individualized rather than treated as a universal prescription.
The SURMOUNT-1 DXA analysis did not find evidence that older participants experienced proportionally greater lean-tissue loss with tirzepatide. The proportion of weight loss represented by fat mass remained broadly similar across evaluated age groups.
The study reported broadly similar body-composition patterns across sexes, with approximately 75% of weight loss as fat mass in females and 73% in males receiving tirzepatide.
Not necessarily. In the SURMOUNT-1 DXA substudy, the proportion of weight reduction represented by fat mass remained broadly similar across weight-reduction tertiles, although the absolute amount of both fat and lean mass lost increased with greater total weight reduction.
DXA lean mass is lean soft tissue excluding bone mineral content. Fat-free mass is broader and includes non-fat components such as muscle, organs, connective tissues, bone and water. They should not automatically be treated as synonyms for skeletal muscle.
For understanding the quality of weight change, yes. Body weight tells you total mass change, while body-composition measurements help identify changes in fat and lean compartments. Functional testing can provide an additional layer of information about muscle health.
No. DXA measures body-composition compartments. Strength and physical performance require separate functional assessments.
Because modern anti-obesity pharmacotherapy can produce substantial weight reduction. Researchers increasingly want to determine how much of that reduction is fat, how much is lean tissue, and whether muscle quantity, quality and function are maintained.
Related Articles
- Vietnam Peptides Knowledge Hub: Peptide Research & Education
- Peptide FAQ: Research, Storage and Usage Questions
- Peptide Products for Recovery, Longevity & Performance Research
- Personalized Peptide Plans for Recovery, Fat Loss & Longevity Goals
Related Research Products
Premium Tirzepatide 20mg Injection Pen
A research-oriented injection-pen format centered on tirzepatide, a dual GIP/GLP-1 receptor agonist. The body-composition evidence discussed in this article comes from published clinical research and should not be assumed to represent the characteristics or performance of any specific research product formulation.
Retatrutide 20mg Injection Pen
A separate multi-receptor research peptide relevant to the broader evolution of metabolic pharmacology. Retatrutide should not be treated as interchangeable with tirzepatide because its receptor architecture is different.
Fat Loss Peptide Plan
Explore the Fat Loss Peptide Plan for a broader educational framework around metabolic and body-composition research. This resource is intended for educational and research-planning purposes and is not individualized medical treatment guidance.
Scientific References
- Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. PMID: 39996356. DOI: 10.1111/dom.16275.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205-216. PMID: 35658024. DOI: 10.1056/NEJMoa2206038.
- Locatelli JC, et al. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes Care. 2024. PMID: 38687506.
- Effects of Tirzepatide on Skeletal Muscle Mass in Adults: A Systematic Review. 2025. PMID: 40895971.
- Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies. 2026. PMID: 42346344.
- Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. 2026. PMID: 41877354. DOI: 10.1111/dom.70666.
- Nutrition support whilst on glucagon-like peptide-1 based therapy. Is it necessary? 2025. PMID: 40401903. DOI: 10.1097/MCO.0000000000001130.
- Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity. 2024. PMID: 39295512.
- Preserving Healthy Muscle during Weight Loss. Adv Nutr. 2017. PMID: 28507015. DOI: 10.3945/an.116.014506.
- Effect of resistance exercise on body composition, muscle strength and cardiometabolic health during dietary weight loss in people living with overweight or obesity: a systematic review and meta-analysis. 2025. PMID: 40909191.
- LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial. BMJ Open. 2026;16(4):e116911. PMID: 42020128. DOI: 10.1136/bmjopen-2026-116911.
- Optimizing Weight Loss in the GLP-1 Era: Preserving Muscle Mass, Function and Metabolic Health Through Precision Nutrition and Resistance Training. 2026. PMID: 42356514.
- Preserving the Metabolic Engine: Muscle as the Therapeutic Target for Cardiovascular Prevention in Obesity Pharmacotherapy. 2026. PMID: 41400708.
Conclusion
Tirzepatide-associated weight reduction is not simply a story about a smaller number on the scale.
The SURMOUNT-1 DXA substudy provides a much more informative picture:
- body weight decreased substantially;
- fat mass decreased even more substantially on a percentage basis;
- lean mass also decreased;
- visceral fat decreased markedly;
- and approximately three-quarters of the weight reduction came from fat mass.
The headline number is therefore approximately 74% fat mass and 26% lean mass — commonly simplified to 75/25.
But the second half of the interpretation is just as important.
Lean mass is not synonymous with skeletal muscle.
And skeletal muscle mass is not synonymous with strength or physical performance.
For that reason, the scientifically mature interpretation is neither:
“Tirzepatide only removes fat.”
nor:
“A quarter of the weight lost is muscle.”
Both statements go beyond what the DXA evidence actually demonstrates.
The stronger conclusion is that tirzepatide produces substantial fat-mass reduction accompanied by a smaller but measurable reduction in DXA-derived lean mass.
For active people in Da Nang, the next question is therefore not simply how much weight can be lost.
It is how to evaluate whether the resulting body composition remains compatible with strength, performance, nutritional adequacy and long-term physical function.
It is a favorable change in body composition while preserving as much functional capacity as possible.
That is the reason body-composition data deserve their own conversation.
Quick Answer
Core Questions: How much fat mass is lost with tirzepatide? How much lean mass is lost with tirzepatide? Is 75% of tirzepatide weight loss fat? Does 25% lean mass mean muscle loss? What did the SURMOUNT-1 DXA substudy find? Does tirzepatide reduce visceral fat? How should active people think about muscle preservation during weight loss? What is the difference between lean mass and skeletal muscle?
Core Statistic: In the SURMOUNT-1 DXA substudy, approximately 74% of body-weight reduction with tirzepatide was attributable to fat mass and 26% to lean mass; commonly summarized as approximately 75/25.
Important Scientific Qualification: DXA-derived lean mass should not be interpreted as pure skeletal muscle mass. Muscle quantity, muscle quality, strength and physical function are distinct endpoints.
Evidence Level: Strong clinical body-composition evidence from the SURMOUNT-1 DXA substudy, with ongoing research into skeletal-muscle quality, function and strategies for lean-mass preservation during incretin-based pharmacotherapy.